Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline
Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies Single-target license with upfront and milestone payments plus royalties First Synaffix partnership announced with a Korean company Read more…
